Rise In Respiratory Disorders Fueling The Growth Of The Market Due To Growing Need For Targeted Pulmonary Therapies Is Supporting Development Across The Inhalable Biologics Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Inhalable Biologics Market Change Between 2026 And 2030?

The inhalable biologics market size has experienced rapid expansion in recent years. It is anticipated to grow from $3.22 billion in 2025 to $3.73 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 15.7%. The growth observed in the historic period is attributable to the increasing prevalence of respiratory diseases, the limitations associated with injectable biologics, advancements in inhalation device technology, a growing biologics pipeline, and expanding hospital-based respiratory care services.

The inhalable biologics market size is set for substantial growth in the upcoming years, with projections indicating an increase to $6.67 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.6%. This expansion throughout the forecast period stems from factors such as the rise in chronic respiratory disorders, the broadening application of inhalable biologics beyond respiratory uses, a growing patient preference for non-invasive therapies, improvements in formulation stability, and increased funding for pulmonary drug delivery research. Significant trends anticipated during this period include the expansion of pulmonary delivery for systemic biologics, the increasing use of dry powder inhalers for biologics, a heightened focus on targeted lung drug delivery, the rising development of inhalable monoclonal antibodies, and the adoption of patient-friendly non-invasive biologic therapies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

What Key Growth Drivers Are Influencing The Inhalable Biologics Market?

A rise in respiratory ailments is anticipated to drive the expansion of the inhalable biologics market in the future. These conditions encompass illnesses and dysfunctions impacting the lungs and other components of the respiratory system, such as airways and nasal passages. Their widespread occurrence stems from escalating air pollution, which exacerbates issues like asthma, chronic obstructive pulmonary disease (COPD), and lung cancer through exposure to harmful particulate matter and other contaminants. Inhalable biologics offer advantages for such conditions by delivering focused treatment straight to the lungs, thereby lessening inflammation and enhancing lung function with minimal systemic adverse effects. For example, data from June 2024, provided by the Australian Institute of Health and Welfare, an Australia-based government body, indicated that in 2023, COPD constituted 3.6% of the overall disease burden and 50% of the burden from respiratory diseases. Consequently, the growing incidence of respiratory conditions substantially contributes to the expansion of the inhalable biologics market.

Which Segment-Based Categories Are Covered In The Inhalable Biologics Market?

The inhalable biologics market covered in this report is segmented –

1) By Type: Peptides And Proteins, Vaccines, Monoclonal Antibodies, RNAi-Based Therapeutics, Other Types

2) By Dosage Form: Dry Powder Inhalers, Metered Dose Inhalers, Nebulizers, Other Dosage Forms

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

4) By Application: Respiratory Diseases, Diabetes, Cancer, Other Applications

Subsegments:

1) By Peptides And Proteins: Insulin, Growth Hormones, Enzyme Replacement Therapies, Other Peptides And Proteins

2) By Vaccines: Influenza Vaccines, Other Respiratory Vaccines

3) By Monoclonal Antibodies: Respiratory Monoclonal Antibodies, Immunomodulatory Monoclonal Antibodies, Other Monoclonal Antibodies

4) By RNAi-Based Therapeutics: RNA-Based Drugs For Respiratory Diseases, Other RNAi-Based Therapeutics

5) By Other Types: Gene Therapies, Small Molecule Inhalable Drugs, Other Innovative Inhalable Biologics

Which Trends Are Contributing To Changes In The Inhalable Biologics Market?

Leading enterprises operating within the inhalable biologics market are prioritizing the development of innovative solutions, such as inhaled insulin, to enhance patient compliance and achieve rapid glycemic control. Inhaled insulin is a type of insulin that reaches the bloodstream through the lungs via inhalation, rather than through injections or insulin pumps. This method involves breathing in a powdered or aerosolized version of insulin, which is absorbed through the respiratory system and quickly enters the bloodstream to help manage blood sugar levels. For instance, in February 2025, Cipla Limited, an India-based pharmaceutical firm, obtained regulatory approval from the Central Drugs Standard Control Organization for Afrezza, recognized as the world’s fastest inhaled insulin, offering a revolutionary, needle-free choice for adults with type 1 and type 2 diabetes. This ultra-rapid-acting insulin begins working within 12 to 15 minutes of inhalation, closely mimicking the natural insulin response to meals and improving blood sugar control. The inhaled insulin provides a more comfortable alternative to multiple daily injections, particularly benefiting patients who experience injection anxiety and boosting adherence to insulin therapy.

Which Companies Are Influencing The Inhalable Biologics Market?

Major companies operating in the inhalable biologics market are Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Moderna Inc., Pfizer Inc. and BioNTech SE, Teva Pharmaceuticals, Baxter International, Lonza Group AG, CanSino Biologics Inc., Cipla Ltd., Insmed Incorporated, Kamada Pharmaceuticals, Vectura Group plc, F. Hoffmann-La Roche Ltd, Iconovo AB, Synairgen plc, Ab Initio Pharma LLC, Nanopharm Ltd, Ocugen Inc., MannKind Corporation

Access The Complete Inhalable Biologics Market Report:

https://www.thebusinessresearchcompany.com/report/inhalable-biologics-global-market-report

Which Regional Market Leads The Inhalable Biologics Market?

North America was the largest region in the inhalable biologics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalable biologics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Inhalable Biologics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24253&type=smp

Browse Through More Reports Similar to the Global Inhalable Biologics Market 2026, By The Business Research Company

Inhalable Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalable-drugs-global-market-report

Inhalation Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-cdmo-global-market-report

Inhalation Anesthesia Market Report 2026

https://www.thebusinessresearchcompany.com/report/inhalation-anesthesia-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795